NCT01911273

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: Pfizer

Condition: Carcinoma, Hepatocellular

Signal summary

Public flags

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

See termination reason in detailed description.